血清Alu甲基化检测对胶质瘤诊断及预后的意义

发布时间：2018-01-25 03:06

  本文关键词： Alu 胶质瘤 甲基化　出处：《南通大学》2014年硕士论文　论文类型：学位论文

【摘要】：目的通过检测胶质瘤患者血清及肿瘤组织中Alu甲基化水平的变化,结合临床病例资料,分析并探讨血清中Alu甲基化水平检测对胶质瘤早期诊断及预后判断的意义。方法收集65例胶质瘤患者肿瘤组织及对应的血清标本,以及30例健康人血清标本作为对照,采用亚硫酸氢盐测序(BSP)法(包括DNA提取与修饰、PCR扩增、测序)来检测胶质瘤患者血清、组织和正常人血清中Alu甲基化水平,结合临床随访资料,进行统计分析。结果胶质瘤患者血清中Alu平均甲基化水平为47.30%(35.40-54.25%),而正常人血清中是57.90%(55.25-61.45%),具有统计学差异(P0.01);肿瘤组织中Alu平均甲基化水平为40.30%(36.80-54.20%),与对应的血清中的Alu甲基化水平具有较高的一致性(r=0.882);在肿瘤组织和病人血清组中,高级别组(14 WHOⅢ级,19 WHOⅣ级)的甲基化水平都低于低级别组(15 WHOⅠ级,17WHOⅡ级,P0.01,P0.01),另外Alu甲基化水平越高也预示着更高的生存率(P0.01,P0.01);ROC曲线分析曲线下面积(AUC)为0.861(0.789-0.933,P0.001),说明血清中Alu甲基化水平的检测具有较高的诊断价值。结论血清游离DNA中Alu低甲基化的检测对于胶质瘤的早期诊断及预后判断有着很好的临床应用价值。本实验为血清游离DNA检测在临床上的广泛应用奠定了基础。
[Abstract]:Objective to detect the level of Alu methylation in serum and tumor tissue of glioma patients and to combine the clinical data. The significance of serum Alu methylation level in early diagnosis and prognosis of glioma was analyzed and discussed. Methods tumor tissues and corresponding serum samples were collected from 65 patients with glioma. The serum samples of 30 healthy people were used as control, and the serum samples of glioma patients were detected by bisulfite sequencing method (including DNA extraction and modified PCR amplification, sequencing). The levels of Alu methylation in tissue and normal serum were combined with clinical follow-up data. Results the average methylation level of Alu in the serum of glioma patients was 47.300.35.40-54.25). In normal people, 57.90 was 55.25-61.45 and there was statistical difference (P 0.01). The average methylation level of Alu in tumor tissue was 40.30 and 36.80-54.20). The level of Alu methylation was consistent with the corresponding serum methylation level. In tumor tissue and patient serum group, the methylation level in high grade group (14 WHO 鈪，

本文编号：1461813